Ana Cebrián

1.2k total citations
19 papers, 840 citations indexed

About

Ana Cebrián is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Ana Cebrián has authored 19 papers receiving a total of 840 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Cardiology and Cardiovascular Medicine, 8 papers in Surgery and 5 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Ana Cebrián's work include Blood Pressure and Hypertension Studies (5 papers), Coronary Interventions and Diagnostics (4 papers) and Chronic Kidney Disease and Diabetes (3 papers). Ana Cebrián is often cited by papers focused on Blood Pressure and Hypertension Studies (5 papers), Coronary Interventions and Diagnostics (4 papers) and Chronic Kidney Disease and Diabetes (3 papers). Ana Cebrián collaborates with scholars based in Spain, United States and France. Ana Cebrián's co-authors include Rupangi C. Vasavada, Karen K. Takane, Adolfo Garcı́a-Ocaña, Andrew F. Stewart, Christian Spaulding, Michel Slama, Patrick Henry, Didier Carrié, Emmanuel Teíger and Christoph Bode and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Ana Cebrián

17 papers receiving 813 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ana Cebrián Spain 9 643 447 159 127 127 19 840
Kensuke Hirasawa Netherlands 15 178 0.3× 401 0.9× 120 0.8× 147 1.2× 222 1.7× 57 795
Friedrich W. Röhl Germany 11 82 0.1× 106 0.2× 40 0.3× 43 0.3× 42 0.3× 21 357
Hidehiko Saito Japan 13 31 0.0× 124 0.3× 51 0.3× 123 1.0× 25 0.2× 26 544
Christelle Maurey France 12 96 0.1× 74 0.2× 19 0.1× 92 0.7× 70 0.6× 41 548
Betsy R. Bond United States 11 48 0.1× 190 0.4× 223 1.4× 50 0.4× 60 0.5× 18 497
Zhenkun Yang China 13 173 0.3× 180 0.4× 83 0.5× 101 0.8× 10 0.1× 53 427
Rieko Goto Japan 13 123 0.2× 40 0.1× 11 0.1× 160 1.3× 44 0.3× 50 486
Kaushik Sen India 12 50 0.1× 21 0.0× 71 0.4× 75 0.6× 51 0.4× 32 452
Kadir Öztürk Türkiye 11 187 0.3× 141 0.3× 14 0.1× 68 0.5× 81 0.6× 30 509
Ronald H. L. Li United States 12 53 0.1× 103 0.2× 86 0.5× 84 0.7× 22 0.2× 40 455

Countries citing papers authored by Ana Cebrián

Since Specialization
Citations

This map shows the geographic impact of Ana Cebrián's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ana Cebrián with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ana Cebrián more than expected).

Fields of papers citing papers by Ana Cebrián

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ana Cebrián. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ana Cebrián. The network helps show where Ana Cebrián may publish in the future.

Co-authorship network of co-authors of Ana Cebrián

This figure shows the co-authorship network connecting the top 25 collaborators of Ana Cebrián. A scholar is included among the top collaborators of Ana Cebrián based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ana Cebrián. Ana Cebrián is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Santamaría, Rafael, Carlos Escobar, Beatriz Palacios, et al.. (2025). Cardiovascular and renal outcomes according to KDIGO stages of chronic kidney disease in the Spanish population: Insights from real-world evidence. Nefrología. 45(8). 501340–501340.
2.
Chilet‐Rosell, Elisa, Andrés Peralta, María F. Rivadeneira, et al.. (2024). Social Determinants as Mediators of the Emotional State of People With Type 2 Diabetes and/or Hypertension During the COVID‐19 Pandemic in Ecuador and Spain. Health Expectations. 27(6). e70123–e70123.
3.
Santamaría, Rafael, Carlos Escobar, Beatriz Palacios, et al.. (2024). Magnitude of chronic kidney disease in Spain. SHILAP Revista de lepidopterología. 45(5). 415–417. 1 indexed citations
4.
Pecoits‐Filho, Roberto, Ana Cebrián, Rafael Santamaría, et al.. (2024). High Prevalence of Unrecorded Stage 3 Chronic Kidney Disease in Australia, Brazil, Canada, England, and Spain: The Multinational, Observational REVEAL‐CKD Study. International Journal of Clinical Practice. 2024(1). 1 indexed citations
5.
Pecoits‐Filho, Roberto, Maria Cristina Ribeiro de Castro, Ana Cebrián, et al.. (2023). #3667 REVEAL-CKD: PREVALENCE OF UNDIAGNOSED STAGE 3 CHRONIC KIDNEY DISEASE IN AUSTRALIA, BRAZIL, CANADA AND SPAIN. Nephrology Dialysis Transplantation. 38(Supplement_1). 2 indexed citations
6.
7.
Seidu, Samuel, Ana Cebrián, Setor K. Kunutsor, & Kamlesh Khunti. (2022). Erectile dysfunction, phosphodiesterase-5 inhibitor use and risk of cardiovascular disease and mortality in people with diabetes: A systematic review and meta-analysis. Primary care diabetes. 16(5). 601–613. 7 indexed citations
8.
Wilding, John, Marc Evans, José Luis Górriz, et al.. (2022). The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review. Diabetes Therapy. 13(5). 847–872. 11 indexed citations
9.
Cebrián, Ana, Carlos Escobar, Beatriz Palacios, et al.. (2021). Including KDIGO cardiovascular risk stratification into SCORE scale could improve the accuracy to better stratify cardiovascular risk. Nefrología. 44(2). 292–294. 1 indexed citations
10.
Cebrián, Ana, et al.. (2018). Poor Glycaemic Control—Identifying Variables Associated with Therapeutic Inertia and Lack of Therapeutic Adherence. Diabetes. 67(Supplement_1). 1 indexed citations
11.
Scheinert, Dierk, Carlo Pratesi, Roberto Chiesa, et al.. (2013). First-in-human study of the INCRAFT endograft in patients with infrarenal abdominal aortic aneurysms in the INNOVATION trial. Journal of Vascular Surgery. 57(4). 906–914. 21 indexed citations
12.
Ormiston, John A., Alexandre Abizaid, John A. Spertus, et al.. (2010). Six-Month Results of the NEVO RES-ELUTION I (NEVO RES-I) Trial. Circulation Cardiovascular Interventions. 3(6). 556–564. 42 indexed citations
13.
14.
Canouï‐Poitrine, Florence, Corinne Alberti, Priscilla Armoogum, et al.. (2009). Cost effectiveness of sirolimus-eluting stents compared with bare metal stents in acute myocardial infarction. Applied Health Economics and Health Policy. 7(1). 19–29. 7 indexed citations
15.
Spaulding, Christian, Patrick Henry, Emmanuel Teíger, et al.. (2006). Sirolimus-Eluting versus Uncoated Stents in Acute Myocardial Infarction. New England Journal of Medicine. 355(11). 1093–1104. 406 indexed citations
16.
Cebrián, Ana, et al.. (2002). Overexpression of Parathyroid Hormone-Related Protein Inhibits Pancreatic β-Cell Death In Vivo and In Vitro. Diabetes. 51(10). 3003–3013. 51 indexed citations
17.
Garcı́a-Ocaña, Adolfo, Rupangi C. Vasavada, Karen K. Takane, et al.. (2001). Using β-Cell Growth Factors to Enhance Human Pancreatic Islet Transplantation*. The Journal of Clinical Endocrinology & Metabolism. 86(3). 984–988. 53 indexed citations
18.
Garcı́a-Ocaña, Adolfo, Rupangi C. Vasavada, Ana Cebrián, et al.. (2001). Transgenic Overexpression of Hepatocyte Growth Factor in the β-Cell Markedly Improves Islet Function and Islet Transplant Outcomes in Mice. Diabetes. 50(12). 2752–2762. 135 indexed citations
19.
Revilla, Yolanda, Ana Cebrián, Elena Baixerás, et al.. (1997). Inhibition of Apoptosis by the African Swine Fever Virus Bcl-2 Homologue: Role of the BH1 Domain. Virology. 228(2). 400–404. 89 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kensuke Hirasawa Breakdown of academic impact, for papers by Friedrich W. Röhl Breakdown of academic impact, for papers by Hidehiko Saito Breakdown of academic impact, for papers by Christelle Maurey Breakdown of academic impact, for papers by Betsy R. Bond Breakdown of academic impact, for papers by Zhenkun Yang Breakdown of academic impact, for papers by Rieko Goto Breakdown of academic impact, for papers by Kaushik Sen Breakdown of academic impact, for papers by Kadir Öztürk Breakdown of academic impact, for papers by Ronald H. L. Li
Rankless by CCL
2026